NewEdge Advisors’s IGC Pharma IGC Stock Holding History

NewEdge Advisors’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14	Closed	-$4	–	4073
2025 Q1	$4	Hold	14	–	–	﹤0.01%	3923
2024 Q4	$5	Buy	+14	New	+$5	﹤0.01%	3878
2024 Q2	–	Sell	-25	Closed	-$10	–	3895
2024 Q1	$10	Hold	25	–	–	﹤0.01%	3776
2023 Q4	$7	Buy	+25	New	+$8	﹤0.01%	3719

Other funds holding IGC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

NewEdge Advisors's IGC Position: Q2 2025 in Review

NewEdge Advisors sold out of IGC Pharma (IGC) in Q2 2025, closing a stake of 14 shares — an estimated $4 sold.

NewEdge Advisors first reported a position in IGC in Q4 2023 and held it in 4 quarters. The position peaked at $10 in Q1 2024. 28 funds tracked by Wall St. Rank hold IGC as of Q2 2025.

NewEdge Advisors reported no remaining IGC Pharma position as of Q2 2025 after selling out during the quarter.
NewEdge Advisors sold 14 IGC Pharma shares in Q2 2025, an estimated $4.
NewEdge Advisors first reported a position in IGC Pharma in Q4 2023 and held it in 4 quarters.
NewEdge Advisors's IGC Pharma position peaked at $10 in Q1 2024.
28 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.